Differential microRNA expression profiles determined by next‑generation sequencing in three fulvestrant‑resistant human breast cancer cell lines

Guo,Juan; He,Keli; Zeng,Hui; Shi,Yu; Ye,Peng; Zhou,Qian; Pan,Zhongya; Long,Xinghua

doi:10.3892/ol.2019.10061

Differential microRNA expression profiles determined by next‑generation sequencing in three fulvestrant‑resistant human breast cancer cell lines

Authors:
- Juan Guo
- Keli He
- Hui Zeng
- Yu Shi
- Peng Ye
- Qian Zhou
- Zhongya Pan
- Xinghua Long
View Affiliations

Affiliations: Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: February 21, 2019 https://doi.org/10.3892/ol.2019.10061
Pages: 3765-3776
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fulvestrant resistance is a major clinical issue in the treatment of endocrine‑based breast cancer. MicroRNAs (miRNAs) are known to serve an important role in tumor chemoresistance. In the present study, the association between miRNA expression profiles and fulvestrant resistance was investigated in human breast cancer cell lines. Three fulvestrant‑resistant breast cancer cell lines, namely MCF‑7‑CC, MCF‑7‑TT and MCF‑7‑21, were established using the human breast cancer cell line MCF‑7 as the parental cell line and fulvestrant as the screening drug in vitro. Next‑generation sequencing was used to determine the miRNA expression profiles in these cell lines. Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed to determine the biological functions of differentially expressed miRNAs. In total, 1,536 miRNAs were detected in all the samples, including 1,240 known miRNAs and 296 predicted miRNAs. It was observed that the differential miRNA expression profiles varied among the three fulvestrant‑resistant cell lines (MCF‑7‑CC, MCF‑7‑TT and MCF‑7‑21), and certain differentially expressed miRNAs were only detected in one or two of the cell lines. A total of 257 miRNAs that were differentially expressed between MCF‑7‑CC and MCF‑7 cells were detected, among which 69 miRNAs were upregulated and 188 miRNAs were downregulated. In addition, 270 miRNAs with significantly different expression between MCF‑7‑TT and MCF‑7 cells were observed, including 180 upregulated and 90 downregulated miRNAs. Between MCF‑7‑21 and MCF‑7 cells, a total of 227 miRNAs were differentially expressed, among which 52 miRNAs were upregulated and 175 miRNAs were downregulated. The miRNAs that were differentially expressed in the three fulvestrant‑resistant cell lines as compared with the parental MCF‑7 cell line were primarily involved in the following biological processes: Biological regulation, extracellular matrix‑receptor interaction, the Notch signaling pathway and focal adhesion. Taken together, the results suggested that miR‑143, miR‑145, miR‑137, miR‑424 and miR‑21 may serve important roles in fulvestrant resistance in breast cancer. The study findings may provide a basis for further research on the treatment of fulvestrant‑resistant breast cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Osborne CK, Wakeling A and Nicholson RI: Fulvestrant: An oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 90 Suppl 1:S2–S6. 2004. View Article : Google Scholar : PubMed/NCBI
3	Tangkeangsirisin W and Serrero G: GP88 (Progranulin) confers fulvestrant (Faslodex, ICI 182,780) resistance to human breast cancer cells. Adv Breast Cancer Res. 03:68–78. 2014. View Article : Google Scholar
4	Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H and Jordan VC: Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. Int J Oncol. 30:509–520. 2007.PubMed/NCBI
5	Tsuboi K, Kaneko Y, Nagatomo T, Fujii R, Hanamura T, Gohno T, Yamaguchi Y, Niwa T and Hayashi SI: Different epigenetic mechanisms of ERalpha implicated in the fate of fulvestrant-resistant breast cancer. J Steroid Biochem Mol Biol. 167:115–125. 2017. View Article : Google Scholar : PubMed/NCBI
6	Hong L, Yang Z, Ma J and Fan D: Function of miRNA in controlling drug resistance of human cancers. Curr Drug Targets. 14:1118–1127. 2013. View Article : Google Scholar : PubMed/NCBI
7	Brennecke J, Hipfner DR, Stark A, Russell RB and Cohen SM: bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 113:25–36. 2003. View Article : Google Scholar : PubMed/NCBI
8	Inui M, Martello G and Piccolo S: MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 11:252–263. 2010. View Article : Google Scholar : PubMed/NCBI
9	Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM and Nephew KP: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 30:1082–1097. 2011. View Article : Google Scholar : PubMed/NCBI
10	Ji S, Shao G, Lv X, Liu Y, Fan Y, Wu A and Hu H: Downregulation of miRNA-128 sensitises breast cancer cell to chemodrugs by targeting Bax. Cell Biol Int. 37:653–658. 2013. View Article : Google Scholar : PubMed/NCBI
11	Hu Q, Gong JP, Li J, Zhong SL, Chen WX, Zhang JY, Ma TF, Ji H, Lv MM, Zhao JH and Tang JH: Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev. 15:5137–5142. 2014. View Article : Google Scholar : PubMed/NCBI
12	Fan P, Yue W, Wang JP, Aiyar S, Li Y, Kim TH and Santen RJ: Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: Evidence from in vitro breast cancer cell models. Endocrinology. 150:2036–2045. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ye P, Fang C, Zeng H, Shi Y, Pan Z, An N, He K, Zhang L and Long X: Differential microRNA expression profiles in tamoxifen-resistant human breast cancer cell lines induced by two methods. Oncol Lett. 15:3532–3539. 2018.PubMed/NCBI
14	Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, et al: Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 66:11954–11966. 2006. View Article : Google Scholar : PubMed/NCBI
15	Jensen BL, Skouv J, Lundholt BK and Lykkesfeldt AE: Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6. Br J Cancer. 79:386–392. 1999. View Article : Google Scholar : PubMed/NCBI
16	Coser KR, Wittner BS, Rosenthal NF, Collins SC, Melas A, Smith SL, Mahoney CJ, Shioda K, Isselbacher KJ, Ramaswamy S and Shioda T: Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci USA. 106:14536–14541. 2009. View Article : Google Scholar : PubMed/NCBI
17	Stokowy T, Eszlinger M, Świerniak M, Fujarewicz K, Jarząb B, Paschke R and Krohn K: Analysis options for high-throughput sequencing in miRNA expression profiling. BMC Res Notes. 7:1442014. View Article : Google Scholar : PubMed/NCBI
18	Friedländer MR, Mackowiak SD, Li N, Chen W and Rajewsky N: miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res. 40:37–52. 2012. View Article : Google Scholar : PubMed/NCBI
19	Fahlgren N, Howell MD, Kasschau KD, Chapman EJ, Sullivan CM, Cumbie JS, Givan SA, Law TF, Grant SR, Dangl JL and Carrington JC: High-throughput sequencing of Arabidopsis microRNAs: Evidence for frequent birth and death of MIRNA genes. PLoS One. 2:e2192007. View Article : Google Scholar : PubMed/NCBI
20	Li J, Witten DM, Johnstone IM and Tibshirani R: Normalization, testing, and false discovery rate estimation for RNA-sequencing data. Biostatistics. 13:523–538. 2012. View Article : Google Scholar : PubMed/NCBI
21	Deng W, Wang Y, Liu Z, Cheng H and Xue Y: HemI: A toolkit for illustrating heatmaps. PLoS One. 9:e1119882014. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Betel D, Wilson M, Gabow A, Marks DS and Sander C: The microRNA.org resource: Targets and expression. Nucleic Acids Res. 36:D149–D153. 2008. View Article : Google Scholar : PubMed/NCBI
24	Rehmsmeier M, Steffen P, Hochsmann M and Giegerich R: Fast and effective prediction of microRNA/target duplexes. RNA. 10:1507–1517. 2004. View Article : Google Scholar : PubMed/NCBI
25	Young MD, Wakefield MJ, Smyth GK and Oshlack A: Gene ontology analysis for RNA-seq: Accounting for selection bias. Genome Biol. 11:R142010. View Article : Google Scholar : PubMed/NCBI
26	Mao X, Cai T, Olyarchuk JG and Wei L: Automated genome annotation and pathway identification using the KEGG Orthology (KO) as a controlled vocabulary. Bioinformatics. 21:3787–3793. 2005. View Article : Google Scholar : PubMed/NCBI
27	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
28	Ng EK, Li R, Shin VY, Siu JM, Ma ES and Kwong A: MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. Tumour Biol. 35:2591–2598. 2014. View Article : Google Scholar : PubMed/NCBI
29	Sachdeva M and Mo YY: miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res. 2:170–180. 2010.PubMed/NCBI
30	Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L, Zhou H and Zhao RC: miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol. 34:1461–1466. 2009.PubMed/NCBI
31	Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K and Mo YY: p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA. 106:3207–3212. 2009. View Article : Google Scholar : PubMed/NCBI
32	Ye P, Shi Y, An N, Zhou Q, Guo J and Long X: miR-145 overexpression triggers alteration of the whole transcriptome and inhibits breast cancer development. Biomed Pharmacother. 100:72–82. 2018. View Article : Google Scholar : PubMed/NCBI
33	Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, Liu M, Gao X, Liu Y, Zhao C, et al: miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer. 13:2202014. View Article : Google Scholar : PubMed/NCBI
34	Gojis O, Rudraraju B, Gudi M, Hogben K, Sousha S, Coombes RC, Cleator S and Palmieri C: The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol. 7:83–89. 2010. View Article : Google Scholar : PubMed/NCBI
35	Eedunuri VK, Rajapakshe K, Fiskus W, Geng C, Chew SA, Foley C, Shah SS, Shou J, Mohamed JS, Coarfa C, et al: miR-137 targets p160 steroid receptor coactivators SRC1, SRC2, and SRC3 and inhibits cell proliferation. Mol Endocrinol. 29:1170–1183. 2015. View Article : Google Scholar : PubMed/NCBI
36	Denis H, Van Grembergen O, Delatte B, Dedeurwaerder S, Putmans P, Calonne E, Rothé F, Sotiriou C, Fuks F and Deplus R: MicroRNAs regulate KDM5 histone demethylases in breast cancer cells. Mol Biosyst. 12:404–413. 2016. View Article : Google Scholar : PubMed/NCBI
37	Zhao Y, Li Y, Lou G, Zhao L, Xu Z, Zhang Y and He F: MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One. 7:e391022012. View Article : Google Scholar : PubMed/NCBI
38	Han Y, Bi Y, Bi H, Diao C, Zhang G, Cheng K and Yang Z: miR-137 suppresses the invasion and procedure of EMT of human breast cancer cell line MCF-7 through targeting CtBP1. Hum Cell. 29:30–36. 2016. View Article : Google Scholar : PubMed/NCBI
39	Zhu X, Li Y, Shen H, Li H, Long L, Hui L and Xu W: miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin (Shanghai). 45:80–86. 2013. View Article : Google Scholar : PubMed/NCBI
40	Xin F, Li M, Balch C, Thomson M, Fan M, Liu Y, Hammond SM, Kim S and Nephew KP: Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics. 25:430–434. 2009. View Article : Google Scholar : PubMed/NCBI
41	Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA and Cohen PA: MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Res. 17:132015. View Article : Google Scholar : PubMed/NCBI
42	Rodriguez-Barrueco R, Nekritz EA, Bertucci F, Yu J, Sanchez-Garcia F, Zeleke TZ, Gorbatenko A, Birnbaum D, Ezhkova E, Cordon-Cardo C, et al: miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev. 31:553–566. 2017. View Article : Google Scholar : PubMed/NCBI
43	Fu X, Han Y, Wu Y, Zhu X, Lu X, Mao F, Wang X, He X and Zhao Y and Zhao Y: Prognostic role of microRNA-21 in various carcinomas: A systematic review and meta-analysis. Eur J Clin Invest. 41:1245–1253. 2011. View Article : Google Scholar : PubMed/NCBI
44	Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
45	Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, et al: MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 7:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
46	Yu X, Li R, Shi W, Jiang T, Wang Y, Li C and Qu X: Silencing of microRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomed Pharmacother. 77:37–44. 2016. View Article : Google Scholar : PubMed/NCBI
47	Zhou Q, Zeng H, Ye P, Shi Y, Guo J and Long X: Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells. Anticancer Drugs. 29:539–548. 2018. View Article : Google Scholar : PubMed/NCBI
48	Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y and Klinge CM: Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 37:2584–2595. 2009. View Article : Google Scholar : PubMed/NCBI
49	Welshons WV, Wolf MF, Murphy CS and Jordan VC: Estrogenic activity of phenol red. Mol Cell Endocrinol. 57:169–178. 1988. View Article : Google Scholar : PubMed/NCBI
50	Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, Iorio MV, Li M, Volinia S, Alder H, et al: MicroRNA cluster 221–222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst. 102:706–721. 2010. View Article : Google Scholar
51	Yeh MH, Tzeng YJ, Fu TY, You JJ, Chang HT, Ger LP and Tsai KW: Extracellular matrix-receptor interaction signaling genes associated with inferior breast cancer survival. Anticancer Res. 38:4593–4605. 2018. View Article : Google Scholar : PubMed/NCBI
52	Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM and Wicha MS: Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 6:R605–R615. 2004. View Article : Google Scholar : PubMed/NCBI
53	Li L, Tang P, Li S, Qin X, Yang H, Wu C and Liu Y: Notch signaling pathway networks in cancer metastasis: A new target for cancer therapy. Med Oncol. 34:1802017. View Article : Google Scholar : PubMed/NCBI
54	Alketbi A and Attoub S: Notch signaling in cancer: Rationale and strategies for targeting. Curr Cancer Drug Targets. 15:364–374. 2015. View Article : Google Scholar : PubMed/NCBI
55	Hoskin V, Szeto A, Ghaffari A, Greer PA, Cote GP and Elliott BE: Ezrin regulates focal adhesion and invadopodia dynamics by altering calpain activity to promote breast cancer cell invasion. Mol Biol Cell. 26:3464–3479. 2015. View Article : Google Scholar : PubMed/NCBI
56	Eke I and Cordes N: Focal adhesion signaling and therapy resistance in cancer. Semin Cancer Biol. 31:65–75. 2015. View Article : Google Scholar : PubMed/NCBI
57	Negoro K, Yamano Y, Fushimi K, Saito K, Nakatani K, Shiiba M, Yokoe H, Bukawa H, Uzawa K, Wada T, et al: Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB. Int J Oncol. 30:1325–1332. 2007.PubMed/NCBI
58	Watson MB, Lind MJ and Cawkwell L: Establishment of in-vitro models of chemotherapy resistance. Anticancer Drugs. 18:749–754. 2007. View Article : Google Scholar : PubMed/NCBI
59	Yang LY and Trujillo JM: Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods. Cancer Res. 50:3218–3225. 1990.PubMed/NCBI